Leptin secretion rate increases with higher CAG repeat number in Huntington's disease patients

Clinical Endocrinology

Volumn 73, Issue 2, 2010, Pages 206-211

  Ahmad Aziz, N ^a   Pijl, Hanno ^a   Frölich, Marijke ^a   Maurits Van Der Graaf, A W ^a   Roelfsema, Ferdinand ^a   Roos, Raymund A C ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; HUNTINGTIN; LEPTIN; RESISTIN;

ADIPOSE TISSUE; ADULT; ARTICLE; BODY COMPOSITION; BODY MASS; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FUNCTIONAL DISEASE; HUMAN; HUNTINGTON CHOREA; MALE; MOTOR DYSFUNCTION; NUCLEOTIDE REPEAT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; PROTEIN SYNTHESIS; WEIGHT REDUCTION;

ADIPONECTIN; ADULT; BODY MASS INDEX; CASE-CONTROL STUDIES; CIRCADIAN RHYTHM; FEMALE; HUMANS; HUNTINGTON DISEASE; LEPTIN; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RESISTIN; TIME FACTORS; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 77954882668     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2009.03661.x     Document Type: Article

References (30)

1. The Huntington's Disease Collaborative Research Group. (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72, 971 983.
2. Aziz, N.A., Swaab, D.F., Pijl, H. et al. (2007) Hypothalamic dysfunction and neuroendocrine and metabolic alterations in Huntington's disease: clinical consequences and therapeutic implications. Reviews in the Neurosciences 18, 223 251.
3. Aziz, N.A., van der Burg, J.M., Landwehrmeyer, G.B. et al. (2008) Weight loss in Huntington disease increases with higher CAG repeat number. Neurology 71, 1506 1513.
4. Trejo, A., Tarrats, R.M., Alonso, M.E. et al. (2004) Assessment of the nutrition status of patients with Huntington's disease. Nutrition 20, 192 196.
5. Djousse, L., Knowlton, B., Cupples, L.A. et al. (2002) Weight loss in early stage of Huntington's disease. Neurology 59, 1325 1330.
6. Phan, J., Hickey, M.A., Zhang, P. et al. (2009) Adipose tissue dysfunction tracks disease progression in two Huntington's disease mouse models. Human Molecular Genetics 18, 1006 1016.
7. van der Burg, J.M., Bacos, K., Wood, N.I. et al. (2008) Increased metabolism in the R62 mouse model of Huntington's disease. Neurobiology of Disease 29, 41 51.
8. Nance, M.A. Sanders, G. (1996) Characteristics of individuals with Huntington disease in long-term care. Movement Disorders 11, 542 548.
9. Myers, R.H., Sax, D.S., Koroshetz, W.J. et al. (1991) Factors associated with slow progression in Huntington's disease. Archives of Neurology 48, 800 804.
10. Farrer, L.A. Meaney, F.J. (1985) An anthropometric assessment of Huntington's disease patients and families. American Journal of Physical Anthropology 67, 185 194.
11. Farrer, L.A. Yu, P.L. (1985) Anthropometric discrimination among affected, at-risk, and not-at-risk individuals in families with Huntington disease. American Journal of Medical Genetics 21, 307 316.
12. Fain, J.N., Del Mar, N.A., Meade, C.A. et al. (2001) Abnormalities in the functioning of adipocytes from R62 mice that are transgenic for the Huntington's disease mutation. Human Molecular Genetics 10, 145 152.
13. Weydt, P., Pineda, V.V., Torrence, A.E. et al. (2006) Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell Metabolism 4, 349 362.
14. Trujillo, M.E. Scherer, P.E. (2006) Adipose tissue-derived factors: impact on health and disease. Endocrine Reviews 27, 762 778.
15. Gaba, A.M., Zhang, K., Marder, K. et al. (2005) Energy balance in early-stage Huntington disease. American Journal of Clinical Nutrition 81, 1335 1341.
16. Mochel, F., Charles, P., Seguin, F. et al. (2007) Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression. PLoS ONE 2, e647.
17. Popovic, V., Svetel, M., Djurovic, M. et al. (2004) Circulating and cerebrospinal fluid ghrelin and leptin: potential role in altered body weight in Huntington's disease. European Journal of Endocrinology 151, 451 455.
18. Pratley, R.E., Salbe, A.D., Ravussin, E. et al. (2000) Higher sedentary energy expenditure in patients with Huntington's disease. Annals of Neurology 47, 64 70.
19. Goodman, A.O., Murgatroyd, P.R., Medina-Gomez, G. et al. (2008) The metabolic profile of early Huntington's disease - a combined human and transgenic mouse study. Experimental Neurology 210, 691 698.
20. Licinio, J., Mantzoros, C., Negrao, A.B. et al. (1997) Human leptin levels are pulsatile and inversely related to pituitary-adrenal function. Nature Medicine 3, 575 579.
21. Morton, A.J., Wood, N.I., Hastings, M.H. et al. (2005) Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease. Journal of Neuroscience 25, 157 163.
22. Huntington Study Group (1996) Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group. Movement Disorders 11, 136 142.
23. Johnson, M.L., Pipes, L., Veldhuis, P.P. et al. (2008) AutoDecon, a deconvolution algorithm for identification and characterization of luteinizing hormone secretory bursts: description and validation using synthetic data. Analytical Biochemistry 381, 8 17.
24. Considine, R.V., Sinha, M.K., Heiman, M.L. et al. (1996) Serum immunoreactive-leptin concentrations in normal-weight and obese humans. New England Journal of Medicine 334, 292 295.
25. Lonnqvist, F., Arner, P., Nordfors, L. et al. (1995) Overexpression of the obese (ob) gene in adipose tissue of human obese subjects. Nature Medicine 1, 950 953.
26. Gong, D.W., Bi, S., Pratley, R.E. et al. (1996) Genomic structure and promoter analysis of the human obese gene. Journal of Biological Chemistry 271, 3971 3974.
27. Hodges, A., Strand, A.D., Aragaki, A.K. et al. (2006) Regional and cellular gene expression changes in human Huntington's disease brain. Human Molecular Genetics 15, 965 977.
28. Luthi-Carter, R., Hanson, S.A., Strand, A.D. et al. (2002) Dysregulation of gene expression in the R62 model of polyglutamine disease: parallel changes in muscle and brain. Human Molecular Genetics 11, 1911 1926.
29. Dunah, A.W., Jeong, H., Griffin, A. et al. (2002) Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 296, 2238 2243.
30. Qiu, Z., Norflus, F., Singh, B. et al. (2006) Sp1 is up-regulated in cellular and transgenic models of Huntington disease, and its reduction is neuroprotective. Journal of Biological Chemistry 281, 16672 16680.